Rezolute's Congenital Hyperinsulinism Drug Receives Encouragement from FDA Despite Missed Endpoint in Phase 3 Study.

Rezolute's congenital hyperinsulinism drug, ersodetug, missed its primary endpoint in a Phase 3 study, but the FDA encouraged the company to submit study reports and analysis datasets. The FDA expressed interest in the drug's potential, despite the missed endpoint. Rezolute plans to proceed with the submission.